Non-Invasive Prenatal Testing (NIPT) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

DUBLIN, January 16, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/322q6g/noninvasive) has announced the addition of the "Non-Invasive Prenatal Testing (NIPT) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


Non-invasive prenatal testing is increasingly being adopted by high risk pregnant women for the screening of common fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), Turner syndrome (monosomy X) and many others. The non-invasive nature of these tests, their accuracy and safety have been the major reasons behind their popularity among gynecologists and expecting mothers. MaterniT21 was the first NIPT launched in October 2011, by U.S. based Sequenom, Inc. and since then has been leading the market with the largest market share. Sources from Sequenom, Inc. indicate that the company accounts for more than 60% unit share of the high risk pregnancy market in the U.S. Harmony, verifi, Panorama, NIFTY, PrenaTest and BambniTest are other commercially available NIPTs for detecting chromosomal abnormalities.

The exponential growth of the NIPT market is supported by factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). As maternal age is closely associated with the increasing risk of developing a fetus with chromosomal abnormalities, rising maternal age is likely to contribute to the increasing incidence of babies born with chromosomal aneuploidies. According to Down syndrome education (DSE), in the U.S., the incidence rate for Down syndrome is 1 in every 830 child births (around 4,700 annually), while in Europe the incidence rate is 1 in every 920 babies born (around 9,000 annually), indicating a large potential consumer base for NIPT. Conventional invasive prenatal genetic tests such as amniocentesis and chorionic villus sampling (CVS) are associated with the chance of miscarriage, which is the prime reason for their replacement with new non-invasive prenatal tests. These new NIPTs are based on the analysis of cell-free DNA floating in the maternal plasma and pose no risk of miscarriage. 


Key Topics Covered: 

1 Preface

2 Executive Summary

3 Global Non-Invasive Prenatal Testing Market Overview

4 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 - 2019 (USD Million)

5 Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 - 2019 (USD Million)

6 Competitive Landscape

7 Recommendations

8 Company Profiles

Companies Mentioned:

• Ariosa Diagnostics, Inc.
• BGI Health
• Berry Genomics Co., Ltd
• LifeCodexx AG
• Natera, Inc.
• Sequenom, Inc.
• Verinata Health, Inc.

For more information visit http://www.researchandmarkets.com/research/322q6g/noninvasive

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets